P
Peter Vandenberghe
Researcher at Katholieke Universiteit Leuven
Publications - 322
Citations - 22259
Peter Vandenberghe is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Leukemia & T cell. The author has an hindex of 69, co-authored 303 publications receiving 20348 citations. Previous affiliations of Peter Vandenberghe include University of Navarra & Ghent University Hospital.
Papers
More filters
Journal ArticleDOI
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine,Ross L. Levine,Martha Wadleigh,Jan Cools,Benjamin L. Ebert,Benjamin L. Ebert,Gerlinde Wernig,Brian J. P. Huntly,Titus J. Boggon,Iwona Wlodarska,Jennifer J. Clark,Sandra A. Moore,Jennifer Adelsperger,Sumin Koo,Jeffrey C. Lee,Stacey Gabriel,Thomas Mercher,Alan D. D'Andrea,Stefan Fröhling,Konstanze Döhner,Peter Marynen,Peter Vandenberghe,Ruben A. Mesa,Ayalew Tefferi,James D. Griffin,Michael J. Eck,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Todd R. Golub,Stephanie J. Lee,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +36 more
TL;DR: High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.
Journal ArticleDOI
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools,Jan Cools,Daniel J. DeAngelo,Jason Gotlib,Elizabeth H. Stover,Robert D. Legare,Robert D. Legare,J. E. Cortes,Jeffrey L. Kutok,Jennifer J. Clark,Ilene Galinsky,James D. Griffin,Nicholas C.P. Cross,Ayalew Tefferi,James M. Malone,Rafeul Alam,Stanley L. Schrier,Janet L. Schmid,Michal G. Rose,Peter Vandenberghe,Gregor Verhoef,Marc Boogaerts,Iwona Wlodarska,Hagop M. Kantarjian,Peter Marynen,Steven Coutre,Richard Stone,D. Gary Gilliland +27 more
TL;DR: The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
Journal ArticleDOI
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia Langemeijer,Roland P. Kuiper,Marieke Berends,Ruth Knops,Mariam G Aslanyan,Marion Massop,Ellen Stevens-Linders,Patricia van Hoogen,Ad Geurts van Kessel,Reinier Raymakers,Eveline J. Kamping,Gregor Verhoef,E Verburgh,Anne Hagemeijer,Peter Vandenberghe,Theo de Witte,Bert A. van der Reijden,Joop H. Jansen +17 more
TL;DR: It is concluded that TET2 is the most frequently mutated gene in MDS known so far, and expression was shown to be elevated in hematopoietic cells with highest expression in granulocytes, in line with a function in myelopoiesis.
Journal ArticleDOI
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Gorica Nikoloski,Saskia Langemeijer,Roland P. Kuiper,Ruth Knops,Marion Massop,Evelyn Tönnissen,Adrian van der Heijden,Theresia N Scheele,Peter Vandenberghe,Theo de Witte,Bert A. van der Reijden,Joop H. Jansen +11 more
TL;DR: Analysis of EZH2 deletions, missense and frameshift mutations strongly suggests that EZh2 is a tumor suppressor in myelodysplastic syndromes.
Journal ArticleDOI
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.
Peter Valent,Amy D. Klion,Hans-Peter Horny,Florence Roufosse,Jason Gotlib,Peter F. Weller,Andrzej Hellmann,Georgia Metzgeroth,Kristin M. Leiferman,Michel Arock,Joseph H. Butterfield,Wolfgang R. Sperr,Karl Sotlar,Peter Vandenberghe,Torsten Haferlach,Hans-Uwe Simon,Andreas Reiter,Gerald J. Gleich +17 more
TL;DR: In the year 2011 Working Conference on Eosinophil disorders and Syndromes, a panel of experts from the fields of immunology, allergy, hematology, and pathology contributed to this project as mentioned in this paper.